Zai Lab Limited

(NASDAQ:ZLAB)

Latest On Zai Lab Limited (ZLAB):

Date/Time Type Description Signal Details
2023-05-18 14:54 ESTNewsZai Lab gets priority review for lung cancer dug repotrectinib in ChinaN/A
2023-05-11 00:06 ESTNewsZai Lab Limited (ZLAB) Q1 2023 Earnings Call TranscriptN/A
2023-05-09 21:59 ESTNewsZai Lab GAAP EPS of -$0.05 beats by $0.88, revenue of $62.79M misses by $2.68MN/A
2023-05-08 19:03 ESTNewsZai Lab Q1 2023 Earnings PreviewN/A
2023-04-27 13:44 ESTNewsZai Lab inks license deal with MediLink for potential cancer drugN/A
2023-03-20 07:26 ESTNewsKaruna/ Zai Lab succeed in late-stage trial for schizophrenia candidateN/A
2023-03-13 23:10 ESTNewsZai Lab Sees Profits On The Horizon As Commercialization AcceleratesN/A
2023-03-06 23:19 ESTNewsZai Lab: Positioned For Growth In The Oncology Treatment MarketN/A
2023-03-03 01:57 ESTNewsZai Lab Limited (ZLAB) Q4 2022 Earnings Call TranscriptN/A
2023-03-02 11:05 ESTNewsZai Lab Limited 2022 Q4 - Results - Earnings Call PresentationN/A
2023-03-01 20:40 ESTNewsZai Lab GAAP EPS of -$4.63 beats by $0.30, revenue of $215M misses by $1.4MN/A
2023-02-14 17:27 ESTNewsZai Lab Limited (ZLAB) Presents at Citi Biotech C-Suite Fireside Chat Series Conference (Transcript)N/A
2023-01-30 09:20 ESTNewsZai Lab's bacterial infection drug gets priority review in ChinaN/A
2023-01-18 14:40 ESTNewsParatek/ Zai Lab antibiotic added for reimbursement in ChinaN/A
2023-01-05 17:53 ESTNewsNovocure, Zai Lab surge as lung cancer therapy meets main goal in late-stage trialN/A
2023-01-05 17:52 ESTNewsWhy did NovoCure stock surge today? Phase 3 data for lung cancer candidateN/A
2022-12-16 15:05 ESTNewsChinese pharmas and biotechs risk of delisting averted as US regulators review auditsN/A
2022-12-13 17:07 ESTNewsZai Labs: Biopharma's Alibaba, But BetterN/A
2022-11-11 03:48 ESTNewsZai Lab Limited (ZLAB) Q3 2022 Earnings Call TranscriptN/A
2022-11-09 17:42 ESTNewsZai Lab GAAP EPS of -$0.17 beats by $1.10, revenue of $57.5M beats by $3.77MN/A
2022-11-08 23:56 ESTNewsZai Lab appoints Zentalis' exec as chief scientific officerN/A
2022-11-08 23:56 ESTNewsZai Lab Q3 2022 Earnings PreviewN/A
2022-08-11 03:55 ESTNewsZai Lab Limited's (ZLAB) CEO Samantha Du on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-10 10:02 ESTNewsZai Lab GAAP EPS of -$0.14 beats by $0.92, revenue of $48.17M beats by $1.04MN/A
2022-08-10 10:02 ESTNewsZai Lab Limited 2022 Q2 - Results - Earnings Call PresentationN/A
2022-08-09 15:25 ESTNewsZai Lab Q2 2022 Earnings PreviewN/A
2022-07-13 10:03 ESTNewsChina accepts Zai Lab's biologics license application for neuromuscular disorder drugN/A
2022-06-11 14:14 ESTNewsZai Lab drug gets 2 breakthrough therapy tags in China to treat lung cancer subtypeN/A
2022-06-03 12:39 ESTNewsNovocure/Zai Lab's TTFields therapy meets main goal in phase 2 gastric cancer trialN/A
2022-05-18 19:00 ESTNewsAs Losses Narrow, Is Zai Lab Finally Finding Its Winning Formula?N/A
2022-05-16 06:13 ESTNewsZai Lab Limited 2022 Q1 - Results - Earnings Call PresentationN/A
2022-05-11 16:09 ESTNewsZai Lab stock gains ~8% after Q1 earnings beat, strong product revenue growthN/A
2022-05-11 16:09 ESTNewsZai Lab Limited (ZLAB) CEO Samantha Du on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-10 19:50 ESTNewsZai Lab GAAP EPS of -$0.09 beats by $1.05, revenue of $46.72M beats by $1MN/A
2022-05-09 22:52 ESTNewsZai Lab Q1 2022 Earnings PreviewN/A
2022-04-29 00:40 ESTNewsTurning Point and Zai Lab fall after lung cancer data for repotrectinib in ChinaN/A
2022-03-22 11:59 ESTNewsZai Lab posts late-stage data for niraparib as maintenance therapy in ovarian cancerN/A
2022-03-16 20:43 ESTNewsU.S.-listed Chinese pharma stocks are on the riseN/A
2022-03-15 14:13 ESTNewsJosh Smiley to join Zai Lab as COON/A
2022-03-11 23:33 ESTNewsZai Lab, Beigene down amid potential violation of U.S. accounting regulations lawN/A
2022-03-11 04:45 ESTNewsZai Lab, Beigene down amid potential violation of foreign government ownership lawN/A
2022-03-09 17:32 ESTNewsZai Lab: Shares Are Cheap, But Not Without ReasonN/A
2022-03-09 00:30 ESTNewsZai Lab Revenue Triples As It Struggles To Break Cycle Of Mounting LossesN/A
2022-03-03 05:16 ESTNewsZai Lab Limited (ZLAB) CEO Samantha Du on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-01 18:28 ESTNewsZai Lab GAAP EPS of -$7.58 misses by $0.73, revenue of $144.3M misses by $3.91MN/A
2022-03-01 00:34 ESTNewsZai Lab FY 2021 Earnings PreviewN/A
2022-02-18 06:26 ESTNewsZai Lab's repotrectinib for lung cancer subtype gets breakthrough therapy tag in ChinaN/A
2022-01-12 15:55 ESTNewsZai lab treats pancreatic cancer patient in China phase 3 trial of Tumor Treating FieldsN/A
2022-01-06 22:45 ESTNewsZai Lab's margetuximab application for HER2+ breast cancer accepted in ChinaN/A
2021-12-16 19:29 ESTNewsZai Lab's Nuzyra OK'd in China as Category 1 drug for pneumonia and skin infectionsN/A

About Zai Lab Limited (ZLAB):

Zai Lab Limited, a biopharmaceutical company, discovers, licenses, develops, and commercializes therapeutics to treat oncology, autoimmune, and infectious diseases in China. The company offers ZEJULA for the treatment of breast cancer and non-small cell lung cancer (NSCLC); and Optune, a cancer therapy to treat glioblastoma multiforme. It also develops QINLOCK for the treatment of gastrointestinal stromal tumors; Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other lymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Bemarituzumab for the treatment of gastric and gastroesophageal junction cancer; and Omadacycline to treat acute bacterial skin and skin structure, and community-acquired bacterial pneumonia infections. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Efgartigimod to reduce disease-causing immunoglobulin G (IgG) antibodies; Retifanlimab to treat microsatellite instability high endometrial cancer; ZL-2309 for the treatment of metastatic pancreatic cancer, metastatic colorectal cancer, and other advanced solid tumors; ZL-1201 to treat solid tumors and hematological malignancies; ZL-1102 for the treatment of psoriasis; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited has license and collaboration agreements with the GlaxoSmithKline; Paratek Bermuda, Ltd.; Five Prime Therapeutics, Inc.; Entasis Therapeutics Holdings, Inc.; Crescendo Biologics Ltd.; Novocure Limited; MacroGenics Inc.; Deciphera Pharmaceuticals, LLC; Incyte Corporation; Regeneron Ireland Designated Activity Company; Turning Point Therapeutics Inc; Cullinan Pearl Corp.; Takeda Pharmaceutical Company Limited; and argenx BV. The company was incorporated in 2013 and is headquartered in Shanghai, China.

ZLAB Quotes by TradingView

See Advanced Chart

General

  • Name Zai Lab Limited
  • Symbol ZLAB
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 1,194
  • Fiscal Year EndDecember
  • IPO Date2017-09-20
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.zailaboratory.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 227.95
  • Price/Book (Most Recent Quarter) 10.89
  • Enterprise Value Revenue 239.45
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$3.50
  • Next Year EPS Estimate -$2.31
  • Next Quarter EPS Estimate -$0.86
  • Operating Margin -616%
  • Return on Assets -23%
  • Return on Equity -37%
  • Revenue 48.96 million
  • Earnings Per Share -$3.12
  • Revenue Per Share $0.63
  • Gross Profit 32.22 million
  • Quarterly Earnings Growth 220.2%
View More

Highlights

  • Market Capitalization 11.91 billion
  • EBITDA -184450048
  • Analyst Target Price $174.24
  • Book Value Per Share $13.32
View More

Share Statistics

  • Shares Outstanding 88.02 million
  • Shares Float 70.76 million
  • % Held by Insiders 118%
  • % Held by Institutions 70.22%
  • Shares Short 1.46 million
  • Shares Short Prior Month 1.63 million
  • Short Ratio 3.79
  • Short % of Shares Outstanding 2%
View More

Technicals

  • Beta 1.14
  • 52 Week High $193.54
  • 52 Week Low $44.77
  • 50 Day Moving Average 159.3
  • 200 Day Moving Average 119.56
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Zai Lab Limited (ZLAB) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Zai Lab Limited (ZLAB) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2019-12-312020-03-19$4.65 million-$0.68-$0.60-14.23%
2019-09-302019-11-27$4.92 million-$1.03-$0.63-63.49%

Zai Lab Limited (ZLAB) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Zai Lab Limited (ZLAB) Chart:

ZLAB chart by TradingView

Zai Lab Limited (ZLAB) News:

Below you will find a list of latest news for Zai Lab Limited (ZLAB) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Zai Lab Limited (ZLAB) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-05-172.50CALL0 0712.51TRUE00
2024-05-1750CALL0 0408.09TRUE00
2024-05-177.50CALL0 0372.71TRUE00
2024-05-17100CALL0 0260.49TRUE00
2024-05-1712.50CALL0 0175.55TRUE00
2024-05-17152.25CALL22 196104.08TRUE2.250
2024-05-1717.50.7CALL3 36781.39FALSE0.70
2024-05-17200.15CALL0 240FALSE00
2024-05-1722.51.15CALL0 10FALSE00
2024-05-17250.09CALL0 10FALSE00
2024-05-17300.05CALL0 10FALSE00
2024-05-17350CALL0 00FALSE00
2024-05-17400CALL0 00FALSE00
2024-05-172.50PUT0 00FALSE00
2024-05-1750PUT0 00FALSE00
2024-05-177.50PUT0 00FALSE00
2024-05-17100PUT0 00FALSE00
2024-05-1712.50.75PUT0 540FALSE00
2024-05-17150.9PUT0 1220FALSE00
2024-05-1717.51.7PUT0 298.91TRUE00
2024-05-17200PUT0 0140.82TRUE00
2024-05-1722.50PUT0 0121.85TRUE00
2024-05-17256.44PUT0 0141.37TRUE00
2024-05-17300PUT0 0236.16TRUE00
2024-05-17350PUT0 0233.47TRUE00
2024-05-17400PUT0 0252.01TRUE00
2024-06-212.50CALL0 0440.77TRUE00
2024-06-2150CALL0 0283.59TRUE00
2024-06-217.50CALL0 0189.28TRUE00
2024-06-21107.3CALL0 1153.17TRUE00
2024-06-2112.50CALL0 0121.1TRUE00
2024-06-21152.29CALL0 2102.98TRUE00
2024-06-2117.51.5CALL1 7875.39FALSE1.50
2024-06-21201CALL2 20485.73FALSE10
2024-06-2122.50.25CALL4 23166.42FALSE0.250
2024-06-21250.6CALL0 1330FALSE00
2024-06-21300.15CALL0 90FALSE00
2024-06-21350.05CALL0 3330FALSE00
2024-06-21400.05CALL0 620FALSE00
2024-06-21450CALL0 00FALSE00
2024-06-21500CALL0 00FALSE00
2024-06-212.50PUT0 00FALSE00
2024-06-2150PUT0 00FALSE00
2024-06-217.50PUT0 00FALSE00
2024-06-21100PUT0 00FALSE00
2024-06-2112.51.3PUT0 4987.12FALSE00
2024-06-21151.95PUT0 877.1FALSE00
2024-06-2117.51.9PUT50 1359.04TRUE1.90
2024-06-21204.6PUT0 1772.25TRUE00
2024-06-2122.57.2PUT0 2266.06TRUE00
2024-06-21259.4PUT0 10386.32TRUE00
2024-06-21306.3PUT0 0132.51TRUE00
2024-06-21359.2PUT0 0113.67TRUE00
2024-06-21400PUT0 0161.67TRUE00
2024-06-21450PUT0 0154.1TRUE00
2024-06-21500PUT0 0167.3TRUE00
2024-09-202.50CALL0 0238.33TRUE00
2024-09-2050CALL0 0191.78TRUE00
2024-09-207.50CALL0 0131.15TRUE00
2024-09-20100CALL0 0107.56TRUE00
2024-09-2012.53.7CALL0 2990.62TRUE00
2024-09-20153.15CALL0 275.87TRUE00
2024-09-2017.53.4CALL0 262.55FALSE00
2024-09-20201.95CALL0 2063.74FALSE00
2024-09-2022.50.9CALL0 2075FALSE00
2024-09-20250.85CALL0 6773.22FALSE00
2024-09-20300CALL0 00FALSE00
2024-09-20350.15CALL1 3066.35FALSE0.150
2024-09-202.50PUT0 00FALSE00
2024-09-2050PUT0 00FALSE00
2024-09-207.50PUT0 00FALSE00
2024-09-20100PUT0 00FALSE00
2024-09-2012.51.5PUT0 60FALSE00
2024-09-20152.55PUT0 150FALSE00
2024-09-2017.54.8PUT0 459.15TRUE00
2024-09-20205.31PUT0 962.62TRUE00
2024-09-2022.53.7PUT0 866.75TRUE00
2024-09-20258.4PUT0 188.75TRUE00
2024-09-203011.1PUT0 389.53TRUE00
2024-09-20350PUT0 086.08TRUE00
2024-12-202.50CALL0 0189.58TRUE00
2024-12-20515CALL0 1134.75TRUE00
2024-12-207.50CALL0 0116TRUE00
2024-12-20109.74CALL0 5104.95TRUE00
2024-12-2012.56.3CALL0 1382.59TRUE00
2024-12-20150CALL0 065.56TRUE00
2024-12-2017.53.4CALL20 1067.73FALSE3.40
2024-12-20202.6CALL0 1765.46FALSE00
2024-12-2022.51.34CALL0 1170.04FALSE00
2024-12-20251.35CALL0 440FALSE00
2024-12-20300.74CALL0 250FALSE00
2024-12-20350.76CALL0 5077.64FALSE00
2024-12-20400.9CALL0 885.51FALSE00
2024-12-20451.55CALL0 140FALSE00
2024-12-20500.37CALL0 11130.53FALSE00
2024-12-202.50PUT0 00FALSE00
2024-12-2050PUT0 00FALSE00
2024-12-207.50.55PUT0 10FALSE00
2024-12-20100PUT0 078.27FALSE00
2024-12-2012.50.8PUT0 20FALSE00
2024-12-20152.6PUT0 430FALSE00
2024-12-2017.54.1PUT0 67663.07TRUE00
2024-12-20205.7PUT0 292661.12TRUE00
2024-12-2022.55PUT0 3277.6TRUE00
2024-12-20258.6PUT0 4961.4TRUE00
2024-12-20309PUT0 44368.45TRUE00
2024-12-203519.8PUT0 61577TRUE00
2024-12-204016.3PUT0 094TRUE00
2024-12-20450PUT0 0106.09TRUE00
2024-12-20500PUT0 0114.06TRUE00
2025-01-172.50CALL0 0121.04TRUE00
2025-01-1750CALL0 0114.14TRUE00
2025-01-177.59.1CALL0 286.24TRUE00
2025-01-17100CALL0 091.92TRUE00
2025-01-1712.54.4CALL0 270.97TRUE00
2025-01-17154.01CALL0 173.68TRUE00
2025-01-1717.53CALL0 865.32FALSE00
2025-01-17201.9CALL0 2169.48FALSE00
2025-01-1722.51.65CALL0 5578FALSE00
2025-01-17251.1CALL0 690FALSE00
2025-01-17300.9CALL0 30FALSE00
2025-01-17350.9CALL0 39103.64FALSE00
2025-01-17400CALL0 088.71FALSE00
2025-01-172.50PUT0 00FALSE00
2025-01-1750PUT0 00FALSE00
2025-01-177.50PUT0 00FALSE00
2025-01-17101.2PUT0 50FALSE00
2025-01-1712.51.9PUT0 18176.3FALSE00
2025-01-17152.9PUT0 170564.63FALSE00
2025-01-1717.54.3PUT0 062.93TRUE00
2025-01-17200PUT0 065.74TRUE00
2025-01-1722.59PUT0 262.89TRUE00
2025-01-17250PUT0 064.44TRUE00
2025-01-17300PUT0 073.9TRUE00
2025-01-17350PUT0 067.92TRUE00
2025-01-17400PUT0 079.71TRUE00

Latest ZLAB Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST27$25.23
Jun 13, 2022 7:59 PM EST100$25.23
Jun 13, 2022 7:59 PM EST49$25.18
Jun 13, 2022 7:59 PM EST6$25.18
Jun 13, 2022 7:59 PM EST100$25.18

Zai Lab Limited (ZLAB) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-17S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1704292/000156459020029580/0001564590-20-029580-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1704292/000031506619000812/0000315066-19-000812-index.htm
2020-02-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1704292/000031506620001289/0000315066-20-001289-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1704292/000090445419000247/0000904454-19-000247-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1704292/000090445420000196/0000904454-20-000196-index.htm
2020-08-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000090445420000552/0000904454-20-000552-index.htm
2019-05-10SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1704292/000092963819000531/0000929638-19-000531-index.htm
2020-02-03SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1704292/000092963820000139/0000929638-20-000139-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1704292/000095010319001958/0000950103-19-001958-index.htm
2019-03-29F-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuershttps://www.sec.gov/Archives/edgar/data/1704292/000095010319004111/0000950103-19-004111-index.htm
2019-05-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000095010319005677/0000950103-19-005677-index.htm
2019-05-01424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1704292/000095010319005712/0000950103-19-005712-index.htm
2019-05-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000095010319005714/0000950103-19-005714-index.htm
2019-05-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000095010319005786/0000950103-19-005786-index.htm
2019-05-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000095010319005917/0000950103-19-005917-index.htm
2019-05-06424B2Prospectus [Rule 424(b)(2)]https://www.sec.gov/Archives/edgar/data/1704292/000095010319005999/0000950103-19-005999-index.htm
2020-01-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000095010320001096/0000950103-20-001096-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1704292/000095010320002781/0000950103-20-002781-index.htm
2020-09-16424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1704292/000104746920004887/0001047469-20-004887-index.htm
2020-09-23424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1704292/000104746920004959/0001047469-20-004959-index.htm
2020-02-11SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1704292/000110465920015242/0001104659-20-015242-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1704292/000110465920019426/0001104659-20-019426-index.htm
2020-09-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000110465920104213/0001104659-20-104213-index.htm
2020-09-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000110465920104219/0001104659-20-104219-index.htm
2020-09-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000110465920105468/0001104659-20-105468-index.htm
2020-09-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000110465920106975/0001104659-20-106975-index.htm
2020-09-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000110465920107187/0001104659-20-107187-index.htm
2020-09-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000110465920109116/0001104659-20-109116-index.htm
2020-10-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000110465920113699/0001104659-20-113699-index.htm
2020-10-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000110465920116998/0001104659-20-116998-index.htm
2019-03-22SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1704292/000114420419015587/0001144204-19-015587-index.htm
2020-01-21POSASRPost-effective Amendment to an automatic shelf registration statementhttps://www.sec.gov/Archives/edgar/data/1704292/000119312520011149/0001193125-20-011149-index.htm
2020-01-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000119312520011154/0001193125-20-011154-index.htm
2020-01-21424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1704292/000119312520011159/0001193125-20-011159-index.htm
2020-01-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000119312520011793/0001193125-20-011793-index.htm
2020-01-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000119312520012405/0001193125-20-012405-index.htm
2020-01-24424B2Prospectus [Rule 424(b)(2)]https://www.sec.gov/Archives/edgar/data/1704292/000119312520013551/0001193125-20-013551-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1704292/000119312520037636/0001193125-20-037636-index.htm
2018-10-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459018024170/0001564590-18-024170-index.htm
2018-10-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459018024568/0001564590-18-024568-index.htm
2018-11-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459018030310/0001564590-18-030310-index.htm
2018-12-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459018030832/0001564590-18-030832-index.htm
2019-03-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459019006625/0001564590-19-006625-index.htm
2019-03-2920-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1704292/000156459019010185/0001564590-19-010185-index.htm
2019-06-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459019021366/0001564590-19-021366-index.htm
2019-06-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459019022165/0001564590-19-022165-index.htm
2019-06-2620-F/AAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1704292/000156459019023549/0001564590-19-023549-index.htm
2019-07-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459019024284/0001564590-19-024284-index.htm
2019-08-2320-F/AAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1704292/000156459019032910/0001564590-19-032910-index.htm
2019-09-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459019033837/0001564590-19-033837-index.htm
2019-12-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459019046994/0001564590-19-046994-index.htm
2020-01-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459020001004/0001564590-20-001004-index.htm
2020-01-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459020001532/0001564590-20-001532-index.htm
2020-03-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459020010986/0001564590-20-010986-index.htm
2020-03-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459020011704/0001564590-20-011704-index.htm
2020-04-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459020015797/0001564590-20-015797-index.htm
2020-04-2920-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1704292/000156459020019745/0001564590-20-019745-index.htm
2020-05-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459020024889/0001564590-20-024889-index.htm
2020-06-17S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1704292/000156459020029580/0001564590-20-029580-index.htm
2020-07-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459020031884/0001564590-20-031884-index.htm
2020-07-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459020032675/0001564590-20-032675-index.htm
2020-08-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459020039799/0001564590-20-039799-index.htm
2020-08-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459020040369/0001564590-20-040369-index.htm
2020-09-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459020042650/0001564590-20-042650-index.htm
2020-09-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459020043044/0001564590-20-043044-index.htm
2020-09-1820-F/AAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1704292/000156459020043994/0001564590-20-043994-index.htm
2019-09-12CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1704292/999999999719006805/9999999997-19-006805-index.htm